Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial

Spigel, David R.; Jotte, Robert M.; Aix, Santiago Ponce; Gressot, Laurent; Morgensztern, Daniel; McCleod, Michael; Socinski, Mark A.; Daniel, Davey B.; Juan, Óscar; Mileham, Kathryn F.; West, Howard; Page, Ray D.; Reinmuth, Niels; Knoble, Jeanna; Chen, Tianlei; Bhore, Rafia; Wolfsteiner, M.; Ong, Teng Jin; Gridelli, Cesare; Thomas, Michael

doi:10.1016/j.cllc.2020.09.007

Cited by 8 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[16] In our patient with pure SCC, nab-paclitaxel plus cisplatin was attempted, as this regimen had been effective in treating SCC of other organs in the past. [17–20] Unexpectedly, the patient developed an acute inferior wall infarction 5 days after the first administration. We concluded that the reason might be related to the aneurysmal dilatation of the right proximal coronary artery combined with the hypercoagulable state of the blood.…”

Section: Discussionmentioning

confidence: 98%

Squamous cell carcinoma of the cystic duct: A case report and literature review

Wang,

Lu,

Hao

et al. 2023

Medicine

View full text Add to dashboard Cite

Rationale: Pure squamous cell carcinoma (SCC) of the gallbladder is a rare malignant biliary tract tumor predominantly found in the body and neck of the gallbladder. However, its occurrence in the cystic duct is even rarer. Given its rarity, no established guidelines or consensus currently exist regarding the treatment of pure SCC of the gallbladder. We report an unusual case of SCC originating from the cystic duct with the intent of providing insights into the therapeutic approach for this type of malignancy. Patient concerns: A male patient presented to our hospital with acute cholecystitis. Unexpectedly, imaging revealed gallbladder malignancy. Diagnoses: Pathologic examination after surgery confirmed SCC of the cystic duct. Interventions: Despite elevated bilirubin levels, we were able to exclude hilar involvement, enabling radical tumor resection. Intraoperatively, we discovered that the tumor was located in the cystic duct, a site associated with a high likelihood of invasion into neighboring organs. The tumor demonstrated a predominantly exophytic growth pattern, which prompted us to refrain from extending the resection range, thereby striking a balance between complete tumor removal and surgical trauma. We performed liver wedge resection only to ensure a negative resection margin while preserving the anatomical structure to the greatest extent possible. Postoperative recovery was rapid and uncomplicated. Pathological examination confirmed pure SCC, which led us to initiate a regimen of nab-paclitaxel and cisplatin, which is known to be effective in other organ SCCs. Remarkably, the patient experienced a rare and severe posttreatment cardiovascular event. Consequently, we switched the patient to a chemotherapy regimen of gemcitabine and cisplatin, which ultimately yielded positive clinical outcomes. Outcomes: no evidence of tumor recurrence was observed within 1 year after surgery. Lessons: The diagnosis and therapeutic strategy for rare tumors such as gallbladder SCC should be meticulously tailored based on their unique characteristics to optimize postoperative patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 98%

Squamous cell carcinoma of the cystic duct: A case report and literature review

Wang,

Lu,

Hao

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…The criticality of the tumor microenvironment and its various components (infiltrating immune cells and mesenchymal cells along with its close association with the extracellular matrix and vasculature) have been reviewed by Chen et al [12]. The literature has discussed the variety of tumor microenvironments in the population depending on the genetic constitution, vasculature, and immunity [13][14][15].…”

Section: Systemic Therapy In Lung Cancermentioning

confidence: 99%

“…Spigel et al [ 14 ] conducted a phase-III randomized clinical trial using nanoparticle albumin-bound paclitaxel in combination with carboplatin induction followed by nanoparticle albumin-bound paclitaxel for maintenance therapy in squamous non-small cell lung cancer (NSCLC) patients. Patients without disease progression after induction treatment were randomized to maintenance nanoparticle albumin-bound paclitaxel combined with best supportive care (BSC) or best supportive care alone.…”

Section: Reviewmentioning

confidence: 99%

Nanotechnology in Lung Cancer Therapeutics: A Narrative Review

Koutu¹,

Gupta²,

Das³

et al. 2023

Cureus

View full text Add to dashboard Cite

To date, cancer continues to be one of the biggest challenges for medical science. Nanotechnology has enabled us to overcome some of the limitations of conventional treatment in lung cancer therapeutics. Recently, US Food and Drug Administration (FDA) has approved certain nanomedicines for clinical administration against lung cancer. This article presents a narrative review of approved nanomedicines in lung cancer with a special focus on the results of recently concluded and ongoing clinical trials. The limitations associated with using nanomaterials as anti-lung cancer therapeutic agents and the possible mechanisms to overcome these limitations are also discussed.

show abstract

“…In recent years, with the rapid development of nanotechnology, nanomedicine has gained significant attention due to its unique properties. Especially, the emergence of nanomedicine has provided new options for the treatment of tumors. − Nanomedicine for lung cancer diagnosis and therapy has also been extensively studied, ,− exhibiting notable advantages such as high safety, specificity, and convenience compared to traditional treatments. − Chemodynamic therapy (CDT) is an emerging cancer treatment strategy that was first proposed in 2016 . In the acidic tumor microenvironment (TME), it utilizes the Fenton reaction or Fenton-like reactions to convert the overexpressed hydrogen peroxide (H 2 O 2 ) into highly cytotoxic hydroxyl radical (•OH) species to kill cancer cells .…”

Section: Introductionmentioning

confidence: 99%

Cu²⁺–Citrate–Chitosan Complex Nanoparticles for the Chemodynamic Therapy of Lung Cancer

Sun,

Zhang,

Zhao

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Lung cancer poses a significant threat to human health. Surgical intervention is the preferred treatment modality for lung cancer, but a large number of patients are deprived of the opportunity for surgery for various reasons and are compelled to undergo radiotherapy and chemotherapy, which entail systemic adverse reactions. In recent years, with the advancement of nanomedicine, chemodynamic therapy (CDT) based on free radicals has been extensively investigated. In this study, we fabricated copper–citrate–chitosan composite nanoparticles (CuCC NPs) by encapsulating copper–citrate complexes with natural chitosan polymers, resulting in a substantial reduction in the biotoxicity of copper ions. The CuCC NPs selectively accumulated in tumor tissues through the enhanced permeability and retention effect (EPR) and gradually degraded within the acidic and glutathione (GSH)-rich microenvironment of the tumor, thereby releasing the loaded copper ions. Through CDT, the copper ions converted the overexpressed hydrogen peroxide (H2O2) in the tumor tissue into hydroxyl radicals (•OH), leading to the eradication of tumor cells. In animal experiments, CuCC NPs exhibited remarkable efficacy in CDT. Further histopathological and hematological analyses demonstrated that CuCC NPs could induce substantial apoptosis in tumor tissues while maintaining an extremely high level of safety.

show abstract

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial

Cited by 8 publications

References 10 publications

Squamous cell carcinoma of the cystic duct: A case report and literature review

Squamous cell carcinoma of the cystic duct: A case report and literature review

Nanotechnology in Lung Cancer Therapeutics: A Narrative Review

Cu²⁺–Citrate–Chitosan Complex Nanoparticles for the Chemodynamic Therapy of Lung Cancer

Contact Info

Product

Resources

About

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial

Cited by 8 publications

References 10 publications

Squamous cell carcinoma of the cystic duct: A case report and literature review

Squamous cell carcinoma of the cystic duct: A case report and literature review

Nanotechnology in Lung Cancer Therapeutics: A Narrative Review

Cu2+–Citrate–Chitosan Complex Nanoparticles for the Chemodynamic Therapy of Lung Cancer

Contact Info

Product

Resources

About

Cu²⁺–Citrate–Chitosan Complex Nanoparticles for the Chemodynamic Therapy of Lung Cancer